CoChat

Resistance to Anti-HER2 Therapies in Gastrointestinal Malignancies

Open access

The DOI matches its Crossref record; 159 of the 165 references it cites were found in a registry or an index.

Abstract

Human epidermal growth factor 2 (HER2) is a tyrosine kinase receptor that interacts with multiple signaling pathways related to cellular growth and proliferation. Overexpression or amplification of HER2 is linked to various malignancies, and there have been decades of research dedicated to targeting HER2. Despite the landmark ToGA trial, progress in HER2-positive gastrointestinal malignancies has been hampered by drug resistance. This review examines current HER2 expression patterns and therapies for gastroesophageal, colorectal, biliary tract, and small bowel cancers, while dissecting potential resistance mechanisms that limit treatment effectiveness.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/cancers16162854

Cites

159 of 159 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Select mechanisms of HER2 targeted resistance: (1) Acquired resistance to HER2 therapy involves compensatory activation of PI3K/AKT/mTOR and MAPK/ERK pathways, facilitated by various mechanisms such as MET amplification interacting with HGF [A], overexpression of HER2-family ligands (EGF, AREG, NRG1) [B], upregulation of phosphorylated IGF-1R [C], activation of Src-promoting signaling pathways [D], PTEN loss-of-function mutation causing PIP3 dysregulation [E], and co-amplifications of CDK6, CCND1, CCNE1 driving cell-cycle progression [F]. (2) The heterogeneous expression of HER2 in tumors contributes to primary and acquired resistance to HER2-targeted therapies. Progressive loss of HER2 positivity is a key factor in acquired resistance. Intratumoral heterogeneity is also common in gastric cancer, even before HER2 treatment (3) Mutations in HER2, together with HER2 and HER3 mutations, activate the PI3K–AKT pathway [G]. The generation of ERBB2d16 (HER2d16), a variant lacking exon 16′s extracellular domain, stabilizes homodimers and activates downstream signaling [H]. Overexpression of p95HER2 produces a truncated HER2 form without the extracellular domain [I] (4) Excessive mucin 4 (MUC4) expression and the CD44–polymeric hyaluronan complex can cause inhibition of Trastuzumab binding to HER2. Figure Abbreviations: AREG Amphiregulin; CCNE1 Cyclin E1 gene; CDK Cyclin; EGF/R Epidermal growth factor/receptor; FGFR3 Fibroblast growth factor receptor 3; HER1/2/3 Human epidermal growth factor rector 1/2/3; HGF Hepatocyte growth factor; IGF-1R Insulin-like growth factor 1 receptor; MET Mesenchymal epithelial transition; NRG1 Neuregulin 1; SRC Proto-oncogene tyrosine-protein kinase Src; PI3K/AKT phosphoinositide 3-kinase/AKT; PTEN phosphatase and tensin homolog; Ras/RAF/MEK/ERK Ras/Raf/MEK/extracellular signal-regulated kinase; Rb Retinoblastoma protein; RTK Receptor tyrosine kinase.
Figure 1 Select mechanisms of HER2 targeted resistance: (1) Acquired resistance to HER2 therapy involves compensatory activation of PI3K/AKT/mTOR and MAPK/ERK pathways, facilitated by various mechanisms such as MET amplification interacting with HGF [A], overexpression of HER2-family ligands (EGF, AREG, NRG1) [B], upregulation of phosphorylated IGF-1R [C], activation of Src-promoting signaling pathways [D], PTEN loss-of-function mutation causing PIP3 dysregulation [E], and co-amplifications of CDK6, CCND1, CCNE1 driving cell-cycle progression [F]. (2) The heterogeneous expression of HER2 in tumors contributes to primary and acquired resistance to HER2-targeted therapies. Progressive loss of HER2 positivity is a key factor in acquired resistance. Intratumoral heterogeneity is also common in gastric cancer, even before HER2 treatment (3) Mutations in HER2, together with HER2 and HER3 mutations, activate the PI3K–AKT pathway [G]. The generation of ERBB2d16 (HER2d16), a variant lacking exon 16′s extracellular domain, stabilizes homodimers and activates downstream signaling [H]. Overexpression of p95HER2 produces a truncated HER2 form without the extracellular domain [I] (4) Excessive mucin 4 (MUC4) expression and the CD44–polymeric hyaluronan complex can cause inhibition of Trastuzumab binding to HER2. Figure Abbreviations: AREG Amphiregulin; CCNE1 Cyclin E1 gene; CDK Cyclin; EGF/R Epidermal growth factor/receptor; FGFR3 Fibroblast growth factor receptor 3; HER1/2/3 Human epidermal growth factor rector 1/2/3; HGF Hepatocyte growth factor; IGF-1R Insulin-like growth factor 1 receptor; MET Mesenchymal epithelial transition; NRG1 Neuregulin 1; SRC Proto-oncogene tyrosine-protein kinase Src; PI3K/AKT phosphoinositide 3-kinase/AKT; PTEN phosphatase and tensin homolog; Ras/RAF/MEK/ERK Ras/Raf/MEK/extracellular signal-regulated kinase; Rb Retinoblastoma protein; RTK Receptor tyrosine kinase.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 159 references

Research works printed but not linked: 1

  1. (2024, May 04). Phase 2 Study of ZW25 Plus First-Line Combination Chemotherapy in HER2-Expressing Gastrointestinal (GI) Cancers, Including Gastroesophageal Adenocarcinoma (GEA), Biliary Tract Cancer (BTC), and Colorectal Cancer (CRC). Available online: https://adisinsight.springer.com/trials/700306473.

Cited by

See all 9

Metadata

Authors
Mo, C., Sterpi, M., Jeon, H., & Bteich, F.
Affiliations
Albert Einstein College of Medicine (US)
Corresponding author
Bteich, Fernand
Venue
Cancers
Publisher
MDPI AG
Published
2024-08-15
Volume
16
Issue
16
Pages
2854
ISSN
2072-6694 (ISSN-L)
OpenAlex
W4401643100
Cited by
8
References
165
Citations by year
2026: 4 · 2025: 3 · 2024: 1
FWCI
0.43
Type
journal article
Language
en
Open access
Locations
  • Cancers (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
  • Health Sciences › Medicine › Oncology › Gastric Cancer Management and Outcomes
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
Keywords
HER2, HER2-targeted therapy, drug resistance, gastrointestinal cancer, HER2-positive gastric cancer, HER2-positive colorectal cancer, biliary tract cancer, small intestine neoplasms, HER2 overexpression, tyrosine kinase inhibitors, resistance mechanisms

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Resistance to Anti-HER2 Therapies in Gastrointestinal Malignancies. https://app.cochat.ai/papers/10.3390/cancers16162854
The paper
Mo, C., Sterpi, M., Jeon, H., & Bteich, F. (2024). Resistance to Anti-HER2 Therapies in Gastrointestinal Malignancies. Cancers. https://doi.org/10.3390/cancers16162854

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.